Patents Examined by Peter J. Reddig
  • Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
    Patent number: 11254752
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: February 22, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Alison Crawford
  • Monoclonal antigen-binding proteins to intracellular oncogene products
    Patent number: 11242405
    Abstract: Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab?)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: February 8, 2022
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
  • Immune cell compositions and methods of use
    Patent number: 11242375
    Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: February 8, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Prasad S. Adusumilli, Michel Sadelain
  • CEACAM6 CAR immune cells to treat cancers
    Patent number: 11242386
    Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 8, 2022
    Inventors: Heman Lap Man Chao, Wah Yau Wong, Baomin Tian, Lakshmi Krishnan, Jamshid Tanha, Marni Diane Uger
  • Vaccines against antigens involved in therapy resistance and methods of using same
    Patent number: 11235043
    Abstract: Methods of reducing, the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 1, 2022
    Assignee: Duke University
    Inventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
  • CD80 variant immunomodulatory proteins and uses thereof
    Patent number: 11230588
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 25, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker, Mark F. Maurer, Joseph L. Kuijper
  • Hybrid immunoglobulin containing non-peptidyl linkage
    Patent number: 11220556
    Abstract: The present invention provides compounds producing compounds having the structure (I). Wherein A is a first polypeptide component of the compound; wherein C is a second polypeptide component of the compound, which polypeptide component comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine, selenocysteine, CP, CPXCP (where X=P, R, or S) (SEQ ID NOs: 128-130), CDKTHTCPPCP (SEQ ID NO: 131), CVECPPCP (SEQ ID NO 132), CCVECPPCP (SEQ ID NO 133) and CDTPPPCPRCP (SEQ ID NO 134), wherein B is a chemical structure linking A and C; wherein the dashed line between B and C represents a peptidyl linkage; wherein the solid line between A and B represents a nonpeptidyl linkage comprising the structure (II).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 11, 2022
    Assignee: BIOMOLECULAR HOLDINGS LLC
    Inventor: Daniel Capon
  • Methods of cancer treatment using tumor antigen-specific T cells
    Patent number: 11219676
    Abstract: The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 11, 2022
    Assignees: SYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.
    Inventors: Xiangjun Zhou, Yanyan Han, Xihe Chen, Xiaoling Liang
  • Methods of treating cancer patients with farnesyltransferase inhibitors
    Patent number: 11207314
    Abstract: The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on genotyping and expression profiling of certain immunological genes and RAS mutation status in the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: December 28, 2021
    Assignee: Kura Oncology, Inc.
    Inventors: Antonio Gualberto, Catherine Rose Scholz
  • Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
    Patent number: 11208494
    Abstract: The present invention includes unique, isolated monoclonal antibodies that bind the PSI domain of human RON (RONPSI), and methods for making and using the same and novel combination therapies of anti-RONPSI antibodies, including humanized anti-RONPSI antibodies, nucleic acids that encode the heavy chain, the light chain, or both the light and heave chains of the antibody, host cells, expression vectors, and wherein the antibody or binding fragments thereof can be further conjugated with one or more cytotoxic or chemotherapeutic agents.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: December 28, 2021
    Assignee: PCM TARGETECH, LLC
    Inventors: Ming-Hai Wang, Hang-Ping Yao
  • Combinations of cabozantinib and atezolizumab to treat cancer
    Patent number: 11198731
    Abstract: This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 14, 2021
    Assignee: Exelixis, Inc.
    Inventors: Gisela Schwab, Christian Scheffold, Colin Hessel
  • Method and reagent for detecting ovarian clear cell adenocarcinoma
    Patent number: 11193936
    Abstract: The present invention aims to provide a method for detecting, with high sensitivity and specificity, ovarian clear cell adenocarcinoma, which is highly malignant, among benign and malignant ovarian tumors having various tissue types, and a reagent that can be used for the method. The present invention provides NT-TFPI2, which is a novel processed tissue factor pathway inhibitor 2 polypeptide, as a new detection marker for ovarian clear cell adenocarcinoma. The detection of ovarian clear cell adenocarcinoma is carried out by measuring the amount of NT-TFPI2, or the total amount of NT-TFPI2 and intact TFPI2. The reagent for detecting ovarian clear cell adenocarcinoma contains an antibody that specifically recognizes NT-TFPI2 and intact TFPI2.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 7, 2021
    Assignees: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOSOH CORPORATION
    Inventors: Noriaki Arakawa, Hisashi Hirano, Etsuko Miyagi, Norihisa Ohtake
  • CD47 antibodies and uses thereof for treating cancer
    Patent number: 11180552
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 23, 2021
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
    Patent number: 11167029
    Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 9, 2021
    Assignee: AFFIMED GMBH
    Inventors: Martin Treder, Uwe Reusch, Jens-Peter Marschner, Stefan Knackmuss
  • Car-expressing cells against multiple tumor antigens and uses thereof
    Patent number: 11161907
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • Anti-glyco-MUC1 antibodies and their uses
    Patent number: 11161911
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: November 2, 2021
    Assignee: GO Therapeutics, Inc.
    Inventor: Thayer White
  • Azide group-containing Fc protein
    Patent number: 11149074
    Abstract: The present invention provides a means capable of efficiently manufacturing a fused substance of an Fc protein and a substance of interest (for example, a peptide). Specifically, the present invention provides an azide group-containing Fc protein represented by formula (1): N3-La-Phe-Lb-Fc??(1) wherein N3 represents an azide group; La represents a bond or a divalent group; Phe represents a residue of phenylalanine or a derivative thereof; Lb represents a lysine residue or an arginine residue, or a peptide linker containing two or more amino acid residues having a lysine residue or an arginine residue at/on the N-terminus; and Fc represents an Fc protein; and the like.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: October 19, 2021
    Assignee: Ajinomoto Co., Inc.
    Inventors: Shigeo Hirasawa, Masumi Taki
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
    Patent number: 11143656
    Abstract: The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 12, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Douglas G. McNeel, Brett B. Maricque
  • Chimeric antigen receptors
    Patent number: 11130820
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 28, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li